RadNet (RDNT) to Release Earnings on Monday

RadNet (NASDAQ:RDNT) is expected to issue its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect RadNet to post earnings of $0.19 per share and revenue of $515.6660 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 2, 2026 at 10:30 AM ET.

RadNet Trading Down 0.6%

NASDAQ:RDNT opened at $70.08 on Monday. The company has a 50-day moving average price of $71.96 and a 200-day moving average price of $74.02. The stock has a market cap of $5.41 billion, a price-to-earnings ratio of -412.21 and a beta of 1.49. The company has a current ratio of 1.87, a quick ratio of 1.87 and a debt-to-equity ratio of 0.82. RadNet has a 12 month low of $45.00 and a 12 month high of $85.84.

Institutional Trading of RadNet

Several institutional investors have recently added to or reduced their stakes in RDNT. RTW Investments LP increased its holdings in shares of RadNet by 39.9% in the 4th quarter. RTW Investments LP now owns 3,938,500 shares of the medical research company’s stock worth $281,012,000 after purchasing an additional 1,122,956 shares in the last quarter. Polar Capital Holdings Plc bought a new stake in RadNet in the 3rd quarter worth about $63,423,000. Price T Rowe Associates Inc. MD raised its position in RadNet by 30.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,699,082 shares of the medical research company’s stock worth $192,581,000 after buying an additional 627,936 shares during the last quarter. Ameriprise Financial Inc. raised its position in RadNet by 79.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,394,552 shares of the medical research company’s stock worth $79,364,000 after buying an additional 618,392 shares during the last quarter. Finally, Defiance ETFs LLC bought a new position in RadNet during the 4th quarter valued at about $37,019,000. 77.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RDNT has been the subject of several research analyst reports. KeyCorp upgraded shares of RadNet to a “strong-buy” rating in a report on Friday, January 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of RadNet in a research report on Monday, December 29th. Barclays raised their target price on RadNet from $79.00 to $86.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. UBS Group set a $92.00 price target on RadNet in a research report on Friday, January 9th. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of RadNet in a report on Thursday, December 18th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $90.33.

RadNet Company Profile

RadNet, Inc is a leading independent provider of outpatient diagnostic imaging services in the United States. Through a nationwide network of fixed-site imaging centers and affiliated joint-venture locations, the company delivers a comprehensive suite of radiology services including MRI, CT, PET/CT, ultrasound, X-ray, mammography, bone densitometry, nuclear medicine and interventional radiology procedures. RadNet also offers teleradiology and imaging management solutions to physician practices, hospitals and healthcare systems.

Founded in 1981 and headquartered in Los Angeles, RadNet has expanded its footprint organically and through strategic acquisitions.